Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory filings indicated that Nvidia had divested all its stake in the company.

The giant semiconductor company exited its previous holding of 7.71 million shares in Recursion Pharmaceuticals, which is making a name for itself by leveraging artificial intelligence to accelerate and enhance drug discovery. NVIDIA had maintained its stake in the company for 2 years and was viewed as a vote of confidence in the AI-driven approach to drug discovery.

Recursion Pharmaceuticals has grown its end-to-end AI drug discovery platform by integrating clinical data to support patient translation. Last year, it unveiled a whole-genome map comprising 46 million images of microglial cells to facilitate the identification of new targets.

On February 18, Recursion announced it will share business updates and report Q4 and full‑year 2025 results on February 25.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a “TechBio” company that utilizes artificial intelligence (AI), machine learning, and high-throughput automation to accelerate drug discovery, aiming to reduce the high failure rates and costs of traditional drug development. It operates a proprietary AI-powered platform called the Recursion Operating System.

While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.